The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences (NASDAQ: WVE), whose shares ...

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well. Here's a recap of the week’s most important stories: Biogen BIIB ...

Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of ...

Shares in Wave rose 53% after the trial data was announced, taking its market cap above the $1 billion threshold. The company ...

Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an ...

KB Home (NYSE: KBH) fell 6% after quarterly EPS missed estimates, due in part to lower margin. The home builder also trimmed its full year margin forecas ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

The stock is trading at $8.18, up $2.84, gaining 53.18% on volume of over 12.4 Million shares. The stock had a days' high of $8.33.

The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...

Biomedicines and its artificial intelligence platform to generate drugs for multiple undisclosed targets. Generate will receive $65 million up front, which includes an equity investment of $15 million ...

European shares were higher today. The eurozone's STOXX 600 rose 0.58%, Germany's DAX gained 0.63% and France's CAC 40 gained ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...